Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
corporate icon
KrosFlo® FS-15 RPM™ System
Discover the KrosFlo® FS-15 RPM™ System, part of our RPM™ (Real-time Process Management) Series, designed to revolutionize process control in bioprocessing. Integrating the CTech™ FlowVPX® in-line spectrophotometer, our system provides real-time insights and PAT-control over UF/DF processes, enhancing efficiency, quality, and productivity.
publications icon
Selective protein quantification for preparative chromatography using variable pathlength UV/Vis spectroscopy and partial least squares regression Publication
corporate icon
Seed Train Intensification
Seed train intensification aims to generate ultra high-density cell cultures at optimal points during cell expansion using a robust cell retention device prior to the inoculation of the production bioreactor.
external link icon
Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting
external link icon
Repligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended December 31, 2011
external link icon
Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
external link icon
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results Wednesday, June 9th 10:00 a.m. EDT
external link icon
Repligen Reports Notice of Allowance of United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
external link icon
Repligen Reports Fourth Quarter and Year 2015 Financial Results
- Constant currency revenue growth of 45% for the fourth quarter, 47% for the year -
- Gross margin expansion of 420 basis points to 57.8% for the year -
- Non-GAAP adjusted EPS of $0.40, an increase of 67% for the year - WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the fourth quarter and year ended December 31, 2015. Below are the Company's performance highlights for these periods, followed by financial guidance for the year 2016 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “2015 was a great year for Repligen, as we executed on our growth strategy and established the Repligen brand in key bioprocessing end-markets, while delivering strong financial performance across all of our product lines. For the year, we reported exceptional product sales
external link icon
Repligen Reports Second Quarter Fiscal Year 2012 Financial Results Achieves Record Bioprocessing Product Sales
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support